DocGo Inc. (DCGO) Earnings Call Transcript & Summary
February 27, 2025
Earnings Call Speaker Segments
Mike Cole
executiveThank you, operator. Before I hand things over to management, I'd like to offer a few comments regarding forward-looking statements. Everything shared on this conference call that isn't a statement of historical fact counts as a forward-looking statement. Terms such as may, will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, and similar expressions might be used to flag those forward-looking statements; such statements don't guarantee future performance, and we can't assure you that our plans, intentions, outcomes, results, or expectations will be achieved or realized. Forward-looking statements carry inherent exposure to significant risks, uncertainties, and assumptions, a great many of which lie outside our control and could cause our actual results or outcomes, or when results or outcomes occur, to differ materially from what those forward-looking statements contain. Among these risks, uncertainties, and assumptions are, without limitation, those addressed in our risk factors and elsewhere in DocGo's annual report on Form 10-K, quarterly reports on Form 10-Q, and other reports and statements DocGo has filed with the SEC, to which your attention is directed. Actual outcomes and results, or when results or outcomes occur, may differ materially from what these forward-looking statements express or imply. Beyond that, references to non-GAAP financial measures appear on today's call. Reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measures are furnished directly as part of this call or included in our earnings release or the current report on Form 8-K that includes our earnings release, which appears on our website, docgo.com, and is also filed with the SEC. The information on this call is accurate only as of the date discussed. Investors shouldn't assume that statements will stay relevant and operative at a later time. We assume no obligation to update any information discussed on this call to reflect events or circumstances after the date of this call, or to reflect new information or the occurrence of unanticipated events, except to the extent the law requires. At this time, it's my pleasure to turn the call over to Mr. Lee Bienstock, CEO of DocGo. Lee, please go ahead.
Lee Bienstock
executiveThanks, Mike, and I appreciate everyone being here today. During the fourth quarter, we invested aggressively, continuing to expand our care gap closure footprint as customer demand stays strong. Beyond that, we keep putting money into our existing operations and management structure so we can support the upcoming stage of expansion throughout our customer verticals. The progress and outcomes from these programs make us very excited, though there is a short term effect on profitability from this spending. We routinely examine our costs looking for efficiency improvements, especially regarding non-field headcount, yet we aim to hold onto the talent base required for our next growth phase. Our ambition is to create a company that lasts 100 years and fundamentally changes healthcare delivery while fulfilling our mission of providing high quality, highly accessible care to everyone. To realize this vision, having a clearly defined value proposition that connects with our customers and the patients we serve is essential. From our early data points, we observe enormous potential for value creation through these efforts, so we intend to keep up this investment. We are bringing on experienced operators and top shelf sales personnel, and we continue making considerable enhancements in our tech stack to meet the rapidly growing needs of our customer base. What we keep getting done really demonstrates the difference we're making in the way care gets provided. Just during 2024, more than 15 million estimated arrival times were computed by DocGo's proprietary tech platform on behalf of our customers. To make care possible throughout more than 1.5 million patient interactions, our clinician network covered upwards of 8.8 million miles. Among those interactions, vaccinations were facilitated for more than 58,000 adults and children, and over 99,000 behavioral health depression screenings were coordinated. Hundreds of thousands of patients were assigned to DocGo for care gap closure programs, and in New York and California we expanded those programs substantially. When everything is added up, our services reached 31 states within the U.S. as well as the UK. It makes me genuinely proud that DocGo has been acknowledged as both a leading innovator and one of the best places to work within healthcare. In just the past year, more than 40,000 applications came in from clinicians and corporate personnel who wanted to be part of our mission of delivering care that is both high in quality and highly accessible to everyone. Our fourth quarter care gap closure program's net promoter score, or NPS, came in above 86, which speaks to how strong our offering is. For context within the healthcare sector, a score above 30 is considered good, anything above 50 is excellent, and surpassing 70 is regarded as world class. The quality of what we offer has left both the people receiving care and the organizations buying from us very happy, and we believe there's a big chance to speed up expansion in this market over the next several quarters, doing so through our own efforts as well as acquisitions. When we sit down with insurance company clients, we don't open by pushing some specific care gap program. What we actually provide is a clinical platform that runs on mobile devices, which health plans can deploy to connect with members who cost them a lot and are hard to get in touch with. That's what makes the relationship so sticky — because the value we deliver to those clients is considerable, they come to see us as partners instead of just another supplier. There's strong proof of this, because a large number of the health plan partners we worked with in 2024 intend to broaden their ties with us considerably, both in terms of what we do and how much we do. Let me spend a moment giving a handful of concrete illustrations. To start, a sizable payer covering the tri-state area, with 3 million members, that had given us a considerable volume of lives to work on care gap closure, has told us it now wishes to move into PCP services, with a particular focus on their unattached and underserved populations, and they are additionally weighing the use of DocGo's mobile clinics to deliver care into communities that stand to gain from better access to healthcare services. Next, a large west coast payer with 5 million members, for whom we handled care gap closure services during 2024, now intends to broaden our relationship so that it covers mobile mammography, PCP, mobile clinics and transition of care services. One more West Coast client wants to expand our transition of care offering by a wide margin. The goal is for it to cover all discharges at two hospitals in that region with the biggest patient volumes, and to add chronic care management for high-risk groups living with diabetes and hypertension. Meanwhile, a large New York insurer that covers 5 million lives is raising its roster of assigned patients from 10,000 Medicaid members to between 40,000 and 50,000 unengaged members during this year. Also, an East Coast payer with 2 million members — which began with a program to close care gaps in bone density scans — now wants to include immunizations as well. When we consider payers through a broader lens, what we consistently hear from our customers is that quality initiatives have become their central obsession. The reason is that CMS, along with individual states across the nation, continually raise the bar on quality measure thresholds, and that drives those plans' ratings lower. Outside of the customers we already serve, there has recently been a surge of inbound interest. We attribute this to payers searching for answers, plus a growing awareness of how much difference in-home delivery of medical care and care gap closure programs can make. In order to expand what we offer in this vertical, we bought PTI Health, a mobile phlebotomy business, earlier this month. This acquisition strikes us as a really strong one that we can scale up significantly, fueled by interest from PTI's current customers as well as the clients on our own list who've been asking about it. Right away, we intend to grow these capabilities in the New York market so we can serve a major national lab partner, and more regions will come after that. Over in our government population health segment, the HPD contract related to migrants finished in the middle of December. We anticipate that every receivable tied to that agreement will be paid off completely before Q2 of this year ends. As for the migrant-linked programs we run alongside New York City Health and Hospitals, our outlook remains that this contract will mostly taper off during the first half of 2025. At year end, the accounts receivable across every one of our migrant-related programs came to roughly $150 million, alongside about $30 million in payables owed to subcontractors, and we believe this will generate a substantial cash flow benefit extending through mid 2025; when it comes to business development, we've achieved meaningful strides at the federal level and have won two contracts for subcontracted work at the VA. Through these agreements, we'll be conducting essential examinations for veterans while enhancing access to care and assisting in clearing the backlog issues the system has encountered; our mobile care delivery model leaves us perfectly situated to support the VA's needs, and we've brought on Dr. David Shulkin, who previously served as secretary of the VA, to assist in steering the company's efforts and to propel growth within the population health vertical.
Lee Bienstock
executiveI also want to share some good news: our mobile x-ray initiative in New York keeps growing, and since we started it late last year, it has now produced more than 2,000 images. Our hospital customer segment, which is mostly medical transportation, kept up its strong performance, with customers expanding in a number of important markets. We entered into a 2-year agreement with the major Texas healthcare system, which let us begin offering services in the Dallas-Fort Worth area, consistent with our approach of entering markets alongside an anchor customer. We also signed a 2-year extension with a leading Tennessee based healthcare system so we can keep delivering services in Nashville, and we just announced that we are starting operations in Chattanooga, Tennessee, to serve that system's facilities in the area; in addition, we are growing our relationship with the largest healthcare system in New York state. Before turning things over to norm, I believe it's worth pointing out that although we kept gross margins flat compared with a year earlier, SG&A measured as a share of revenues during the fourth quarter was much higher than it has been in recent periods. We made the choice, and will keep making the choice, to sustain and put money into our infrastructure so we are ready for the growth opportunities that lie ahead. Because migrant related revenue fell so quickly, we gave up a great deal of the leverage that a larger revenue base provides. We see this as something temporary and expect that we can pair the customer expansions already in progress with accretive M&A opportunities, which should let us get back to a much larger revenue base, all while preserving the highest quality standards throughout this transitionary period. If our confidence in the growth opportunity ahead were not strong, we would be making deeper cuts to bring that SG&A percentage back in line with historical levels, but that is not the situation. The strategic value of being in the home and reaching populations that have traditionally been hard to reach in order to deliver preventative care is becoming clearer and clearer to customers, and the pace of inbound inquiries and the pipeline overall has never been stronger; now is the moment to invest in our future, build critical mass and keep delivering exceptional quality in the field, and we could not be more excited about what lies ahead. With that, I'll hand things to Norm for the financials. Norm, please go ahead.
Norman Rosenberg
executiveThanks, Lee, and good afternoon. Prior to walking through the complete set of Q4 results, I want to begin by talking about how we performed relative to the guidance we most recently issued. Our fourth quarter results came in under the range we had announced back in November, especially when it comes to adjusted EBITDA, where the actual Q4 figure missed our implied November guidance range by roughly $10 million. Looking at what drove this, our top line landed at roughly $9 million, which was 7% below what we had projected. That shortfall was entirely attributable to revenue tied to migrants, driven by us shutting down select locations sooner than originally planned in a controlled manner, along with reductions in certain services at locations we kept running. The adjusted EBITDA gap included $5.3 million from that revenue miss. Beyond that, about $1.5 million reflects added spending on our Care Gap closure business, showing up in both COGS and SG&A on the income statement. We also saw a shortfall driven by $3.2 million in costs we hadn't anticipated, scattered across various self-insured coverage categories. Turning now to how operations actually performed in the fourth quarter and across all of 2024: revenue for Q4 of twenty twenty four totaled $120.8 million, down 39% compared with $199.2 million during the same period in 2023. Every bit of that year-over-year drop stemmed from migrant projects. As we've laid out in prior quarters, our work tied to migrants hit its high point in Q4 of 2023, then began tapering off in May of 2024 when we pulled out of the sites located in New York City. Looking back at twenty twenty four, every one of the HPD locations had been shut down by the time the year closed, and whatever migrant-related work still remains with New York City Health and Hospitals should be largely wrapped up around the middle of this year. Turning to the full year, we brought in $616.6 million in revenue during 2024, a 1% decline compared with 2023. In Mobile Health, fourth quarter 2024 revenue came to $71.8 million, which represents a 52% drop versus the fourth quarter of 2023 — the period when our migrant business reached its highest point. Across the full year, Mobile Health generated $423.1 million in revenues, 4% below what we saw in 2023. In the fourth quarter of 2024, revenue from medical transportation reached $49.1 million, representing roughly a 1% gain over the transport revenues reported for Q4 2023. For the full year 2024, transportation revenues came in 7% above 2023 levels, and over the last three years they've grown at a compound annual rate of 32%. With multiple contract wins secured recently and a strong pipeline in place, we feel confident about our expectation of 15% annual revenue growth for 2025 and beyond. Our net loss for Q4 2024 totaled $7.6 million, whereas the fourth quarter of 2023 brought net income of $8 million. When we look at the entire year, net income climbed to $13.4 million during 2024, which represents a 34% gain over the $10 million recorded in 2023. For the fourth quarter of 2024, adjusted EBITDA came in at $1.1 million, versus $22.6 million in the same quarter a year earlier. Across the full year, adjusted EBITDA reached $60.3 million, marking a 12% rise from $54 million in 2023. The adjusted EBITDA margin for all of 2024 stood at 9.8%, an improvement from 8.6% for the whole of 2023. Total GAAP gross margin percentage in Q4 2024 was 30.8%, a decrease from 31.2% in Q4 2023. Adjusted gross margin, which strips out depreciation and amortization, came to 33.5% during the fourth quarter of 2024, matching the adjusted gross margin reported for the fourth quarter of 2023. In Q4 2024, the Mobile Health segment's adjusted gross margin was 35.9%, an increase from 32.2% in Q4 2023; meanwhile, adjusted gross margins in the transportation segment were 30.1% during Q4 2024, a drop from 37.4% in Q4 of 2023, a quarter that had gained from several one time items. Transportation margins continued to face pressure in Q4 from leftover subcontractor costs in one of our bigger markets. Even so, by the time Q4 came to a close, we had eliminated nearly all of those subcontractor expenses, as we were able to fill staffing shortages by bringing on new field employees. Now looking at operating costs: in the fourth quarter of 2024, SG&A accounted for 39.7% of total revenues, up from 27.6% during the same period in 2023. Nevertheless, when you look at actual dollar figures, SG&A was down 13% compared with the fourth quarter of last year. As revenues decreased through the second half of 2024, we observed SG&A rising as a percentage of total revenues, which undid the operating margin expansion seen during the second half of 2023 and early 2024; on top of that, as Lee noted earlier, we made aggressive investments in our payer vertical and additional mobile health services; those outlays were directed at personnel, marketing, billing, credentialing, technology, and establishing and outfitting base locations for our personnel in those markets. Consequently, Q4 saw a halt in our pattern of sequentially lower SG&A costs, something we believe will prove temporary. Starting in the fourth quarter of 2023, the point at which revenue tied to migrants reached its highest level, we've observed overall SG&A declining sequentially at the same time, though by a lesser degree; across the first quarter of 2024, our SG&A was down 7% versus where it stood in Q4 of 2023. Then came a further 11% reduction in SG&A during Q2, followed by an additional 13% decline in Q3; however, in the fourth quarter of 2024, SG&A climbed about 20% relative to Q3, which stemmed from the items mentioned earlier. Even as we continue putting money into our growing business lines, we do expect that quarter-over-quarter decreases in SG&A will resume beginning in Q1 of 2025. Moving on to our balance sheet now, an area where we achieved major progress during 2024 and one that is going to be essential to our capacity to carry out the growth plans Lee just described. At December 31st, 2024, total cash and cash equivalents, inclusive of restricted cash, stood at $107.3 million, versus $72.2 million at the close of 2023 — a roughly 50% year-over-year gain. Even with roughly $14 million going to repurchase shares in 2024 and an additional $5 million directed at our Firefly Health equity investment, we still increased our cash balance; our operations generated $70.3 million in cash flow across 2024, a striking turnaround compared with 2023, when operating cash flow was negative $64.2 million. That said, fourth-quarter operating cash flow came in below our expectations, largely because payments from New York City's Department Of Housing Preservation And Development, or HPD, arrived more slowly than we had projected. Specifically, a pair of monthly invoices totaling about $35 million were payments we had expected to collect during Q4 but in the end did not. So far in 2025 we have brought in substantial amounts from HPD, and our expectation continues to be that we will collect all remaining balances, which should strengthen our cash position further and thereby expand our available investment capital. Net accounts receivable kept declining thanks to collecting on our bigger invoices, and also reflecting the drop in migrant related revenues we saw across the back half of 2024. Net accounts receivable finished the year at $210.9 million, a 20% reduction from $262.1 million at the conclusion of 2023, even though revenues were basically identical across both years. So because of that, our DSO — days sales outstanding — finished 2024 at 125 days, which is a good improvement from where we ended 2023, at 153 days. We still want to get consolidated DSO into the 90-to-100-day range by roughly the middle of 2025, as we collect on those larger, older municipal invoices. Our biggest customers keep paying on a regular basis, and cash keeps coming in — we got several sizable payments just this week as we work on converting accounts receivable into cash. And finally, on guidance and our 2025 outlook, we're still expecting full year revenues of between $410 million and $450 million. We also expect gross margins to stay consistent with, or improve modestly over, those from 2024. Because we anticipate continued investment in our new business lines, we foresee EBITDA margins landing in the mid single digits. That said, as our sizable accounts receivable base keeps contracting through our collection efforts, we expect cash flow from operations in 2025 to be substantially above the $70 million in operating cash flow we delivered in 2024. With that, I’d like to hand the call back to the operator for Q&A.
Pito Chickering
analystAbout the 2025 revenue outlook — on the previous quarter's call, you said the base business would land between $360 million and $400 million, with migrants contributing $50 million, and you expected a much sharper drop-off in migrant revenue during Q4. So is your latest assumption that the base business accelerates in ‘25, or are you still counting on that $50 million from migrants in 2025?
Lee Bienstock
executiveHey, Peter. Yes, of course — appreciate you asking. During our prior call, we said migrant revenues should come in, as you noted, at $50 million for this year. Fair to say the migrant picture is pretty fluid and dynamic at the moment. We're leaving our revenue outlook unchanged for this year, though in my view there's a real chance the ongoing migration keeps happening — away from migrant-related revenues and toward base business revenues. So it's certainly conceivable that migrant-related revenues come in under that $50 million range, and in our forecast, should we shift those operations and personnel toward the growing base business revenues we're seeing at present, any migrant-related revenues would be substituted by base business revenues.
Pito Chickering
analystThat's a fairly substantial expansion of the base business. I mean, and at this point we're roughly almost 2 months into the year. I mean, do you believe the base business can actually add another $25 million, $30 million, $40 million sort of on top of what we guided to back in November?
Lee Bienstock
executiveYes, we're really thrilled about where the base business stands at the moment. To give you one illustration, since you brought it up, our pipeline for the base business is very strong. We've got roughly 27 deals in the pipeline for municipal contracts, close to 30 to 29 health system deals in the pipeline. We have in excess of 120 payer and provider deals. So we have an extremely strong pipeline, something the company has spent all of last year working on as we moved away from the migrant related contracts and as we shift toward more evergreen municipal work, as I was explaining earlier on the call; so we have an extremely strong pipeline. Many of our customers are in expansion mode at the moment. As I said, we're putting investment into that, and so we feel really good about the pipeline. And as the migrant related projects wind down, our aim is to move a lot of that corporate personnel and that field staff over to those growing budding base business revenues.
Pito Chickering
analystAll right. And when we compare the margin guidance from last November with what we have today, it appears there's roughly $17 million in fresh investments needed to move from 8% to 10% to 5%. Where precisely do those $17 million of investments go in order to grow? To keep revenues flat, that just strikes me as a fairly sizeable sum being invested. Could you provide more specifics on why that spending is necessary now when a few months back you wouldn't have thought you'd need it?
Lee Bienstock
executiveYeah, I'd say a few of the major categories — number one, we're putting money into the tech stack and will keep doing so. At the close of Q4, one action we took was automating the patient engagement process, which let us substantially boost bookings for our Care Gap closure programs. On the prior call I noted that we nearly hit a 1,000 visit per week exit rate for the Care Gap business as the year ended. So investments in the tech stack will keep being made. We keep adding well trained field personnel, especially LPNs, to enter the home and provide the care; those field personnel are being trained across a very, very broad skill set. In the home we perform over 35 distinct care gap closure procedures, so our clinicians receive training for this wide scope of practice, which our customers find very attractive; therefore we want to ensure our field personnel have the right technology and the right training to deliver an exceptional experience in the field, and we're putting substantial money into that. I'd add that we've also been investing in our business development personnel to keep driving the pipeline and push some of these deals forward. And so we'll keep making investments in our corporate staff too, along with training for the field staff. Those are the main areas.
Norman Rosenberg
executiveYes, Pito, this is Norman. Let me build on that point. Picking up on Lee's remarks—part of what we're discussing ties back to discretionary spending on our end. For several quarters now, we've been talking about how we need to right size SG&A, keeping it at a percentage of revenue fairly close to historical levels. But when we look at this realistically—and Lee hinted at this in what he said—we're finding places where we hesitate to remove particular kinds of infrastructure and corporate overhead costs, since the people involved will play a major role in growing some of the programs we've discussed. So it isn't as though we've abandoned cost cutting; we're deeply, deeply committed to it, and everyone at this company is deeply committed to it. As we move through 2025, you'll see the results of that. That said, we're approaching it in what might be a more measured fashion; therefore, the path those corporate overhead costs take as they decline—with that path shifting—is among the main reasons we expect the EBITDA margin to differ from our estimate a few months back.
Pito Chickering
analystAll right. Let me return to that topic. So for my first question, I’m just doing a bit of quick math here. What I mean is, previously the goal was roughly 50 million migrants in ’25, or else keeping revenues flat, so what we’re hearing is that the base business is improving. If I were to offset, let’s say, $37 million of that — I’m just making up this figure — that works out to roughly a 10% increase in the base business compared with where things stood in November. Have those deals been finalized yet? In other words, by today, have you already signed 10% more deals than you had back in November? Again, since we’re examining the leverage here — SG&A leverage along with gross margin, and with this margin declining — have those deals been finalized yet? Thank you.
Lee Bienstock
executiveYes, at the beginning of this year, and as we wrapped up last year, we signed 10% more deals; and on top of that, we also have those extra deals in the pipeline that we keep advancing.
Analyst
analystHello, Gabby here, filling in for Sarah. I'd like to ask about that $3.2 million in unexpected costs tied to the EBITDA miss. What kind of confidence can you give us that this won't happen again in 2025?
Norman Rosenberg
executiveYeah, good question. Hi, Gabby, this is Norm. Well, the first point I'd make is that with a self-insured setup like ours, you're definitely dealing with some unpredictability regarding what those figures will look like, unlike a fully insured arrangement where you simply pay a premium and, for the most part, you know exactly what that premium will be. In that case, all you're doing is forecasting how the premium will change annually. In our situation, clearly, because we're self insured, claims will arrive either above or below what we set aside for them. There's also the IBNR component, which accounts for claims that have been incurred but not yet reported. So fluctuation is inevitable; it can rise, it can fall. Plenty of variables can affect that. So claiming it won't happen again is difficult, though typically our reserving approach means that if you reserve in a given quarter, you're likely adequately reserved for the following couple of quarters. One thing I'd highlight, and we talk about this internally here at least once a month, is that we're saving, I'd guess, in the millions, possibly more than $10 million annually, by including workers' comp, auto, and even our health insurance under our captive insurance company; actually, we're even exploring the possibility of shifting additional insurance lines such as cyber, general liability, and professional liability into that structure too. It's served us well. Broadly speaking, take ambulance insurance, or the auto portion and the liability portion as an illustration—those tend to be extremely, extremely costly and extremely overpriced. What we've discovered is that our own experience has been significantly better than what it otherwise would be; and we're regularly benchmarking it against the rates available in the market. So we're prepared to tolerate some variability in that expense. This quarter we experienced the negative side, but over time it comes in lower than it otherwise would. So when we evaluate it on a project basis over time, we're clearly still far ahead.
Analyst
analystAnd if I may, let me quickly add one more thing. I believe you said during the prepared remarks that SG&A would decline sequentially across the quarters of 2025. Is that measured in dollars or as a percentage?
Norman Rosenberg
executiveWhat I actually said was that a sequential decline had been seen in 2024, starting from my baseline of Q4 2023, which represented a peak both as a percentage and in dollar terms. It dropped in Q1, dropped again in Q2 and Q3, then rose in Q4. My point is this: we would expect — we fully expect — that in Q1 of 2025, SG&A in dollar terms will come in below what it was in the Q4 we just reported; as for percentage, looking across the full year, I'd say most likely, given how revenues are trending — and that obviously matters a great deal when you're calculating what portion of revenue SG&A represents — so I'd say Q1 will be better than what we saw in Q4. Q2 will be roughly at the same level as Q1, perhaps slightly higher as a percentage. But once Q3 and Q4 arrive, we're going to move much closer to that level seen before Q4 of this year, as some of that revenue that Lee referenced earlier comes through. So those contract wins will turn into actual revenue; in terms of absolute dollars, we would expect to see sequential declines in absolute dollar SG&A across the year.
Richard Close
analystSorry, I got on the call a bit late. Lee, could you give us the specific migrant revenue figure for the fourth quarter, and also for the entire year? I'm just trying to figure out whether the core business reached that $240 million to $260 million kind of target you all had in mind?
Lee Bienstock
executiveOf course. Hello, Richard. Micro revenues came in at roughly $55 million during Q4, and to answer your question, for the whole year it's around $370 million. We did reach it — on our prior call we had communicated that the range we anticipated for the base business was $240 million to $260 million, and for that base business range, we did achieve the revenue guidance.
Norman Rosenberg
executiveYes, we’re about $246 million, $250 million in that area.
Richard Close
analystI apologize for joining the call behind schedule. Norm, I was quickly reviewing my notes and something is nagging at me — didn’t we see an insurance matter like this arise a couple of years back, or am I misremembering? Is there a method to stop this from happening, say by being more cautious in how you handle guidance and similar items, so that we avoid a repeat?
Norman Rosenberg
executiveRegarding a couple of years ago, I don’t know what you mean, but on the question of looking ahead and keeping this from recurring, the most effective prevention is to have it surface at this point. To clarify, we’ve been conservatively reserved, and our involvement in the captive insurance business is fairly recent. It’s only been a couple of years. As we gain maturity, as we observe how matters unfold, the sequencing of events — suppose there’s an ambulance-related accident, and you watch how that generally evolves with time: in year one the claim is at one level, in year two it moves to another, various factors shift; we examine frequency and severity and every other element that someone who’s been in insurance as long as I have enjoys considering, and we have an excellent team handling that. So as our reserving becomes more conservative and as we ensure we establish an IVNR for claims that have not yet occurred, that lets us essentially rely on accounting to even things out, rather than being stuck in a position where each claim arrives, I report it, and you’re at the mercy of when those claims happen to come in; my hope is that this will carry us a great distance toward accomplishing precisely that — evening out insurance expenses as we move forward.
Richard Close
analystAnd clearly, you folks have been doing well when it comes to bringing in new contracts — the pipelines, plus every one of the units or divisions, look strong across all 3. One issue that people have raised ever since you became a public company is that there is never a lack of new business, yet there are things like upfront costs and these investments. Given the investments being made at present, I guess, if you're delivering on your pipeline, do you believe you'll need yet another set of investments down the road to deliver on that pipeline should you win it? How are you folks approaching that?
Lee Bienstock
executiveCertainly. That's an excellent question, Richard. What I'd say is that, more than anything, our thinking has evolved to a degree, and honestly, we've refined how we approach the set of deals we pursue — is that right? The company had been tilted pretty strongly toward things like responding to crises, handling emergencies, which is baked into who we are as an ambulance business, and many of the municipal mobile health contracts we were landing and chasing tied back to crisis situations. Because of that, they'd launch and then wind down, launch and wind down, and that pattern demands capital spending. Right now, our pipeline is genuinely built around evergreen possibilities; take our care gap closure operation — it exists today and it will still exist as we approach the close of the year. Actually, it keeps expanding throughout the year because insurers try to push further and further ahead as the months pass. Beyond that, unfortunately, some patients will always be disengaged, lack attribution, face barriers to access, or live with long-term illnesses. As a result, those rosters, we've observed, already roll over from one year into the next — from the prior year to this one — turning into a perennial source of revenue for us. When those individuals become primary care patients, we then serve as their ongoing primary care provider over the long term, and so forth; similarly, on the municipal side, we are exploring ways to deliver services to disabled veterans and to people living in communities that are difficult to access — not so much crisis response, but instead health evaluations, health screenings, and other kinds of preventative care. The company's direction is shifting toward care that's proactive, preventative, and focused on the long term. We began assembling that pipeline during the previous year, and by late last year and on into the current one, it has begun delivering results—something we're genuinely thrilled about. As capacity opens up now that migrant-related efforts are winding down, you should expect us to keep expanding that pipeline. We plan to direct an increasing share of what we have toward those chances, and from that point the pipeline will grow, and those efforts will be evergreen, needing less of the starting, stopping, and kind of spending required to get them moving. My sense is that money will come once contracts are won. Additional vehicles will be introduced. As one example, we just brought in an ADA fleet—vehicles with accessibility features designed for disabled veterans—as part of expanding that segment. It's unclear how big it will get, but these programs are evergreen by their nature, which means backing for our veterans will never go away. That’s the kind of opportunity and pipeline we’re going after, and it will remain evergreen, something I believe will be hugely beneficial to this company.
Richard Close
analystFor my last question, perhaps regarding transportation — what's your outlook on that segment's growth rate over the long haul?
Lee Bienstock
executiveThe opportunities for expansion in transport have us quite enthusiastic. Like Norm said, that unit has been expanding at a compounded rate above 30% each year across the last 3 years. As I noted, we currently have roughly 30 health system agreements in our pipeline. Many of those are contracts tied to transport; thus we believe there's room for that unit to keep expanding. Our target for growth in that unit stands at 15%. I should note that expansion there arrives in a stepwise manner: we ink deals with new large health systems and onboard them, which contributes substantially to revenue, after which we pursue the following one and then add it too. So as we sign these health systems, we onboard them. Our team, I believe, is performing beautifully on that front. Our tech platform, I'd say candidly, is the finest in the sector. Health systems seek to partner with us, first, owing to our service quality and the field team being outstanding, yet additionally because our tech platform truly sits at the forefront of what's being built across the industry; and we're leveraging that tech platform to basically also oversee our expanding fleet in the field that's running these care gap closure programs. So we've truly excelled at extending the tech platform from transport over to the mobile health portion of the business, where we now have — as I was saying — we finished the year at roughly 1,000 care gap closure visits within a single week at the close of last year. That's a substantial number of units deployed in the field. They're going, we'll ensure we oversee things there and that Symphony, as I refer to it in the field, matches the right clinician with the right diagnostics for the right patient need, the right care gap closure, trained to deliver a high quality service. And so we're leveraging that tech platform we built on the transport side, and we're extremely, extremely enthusiastic about the chance to truly take that tech platform and deploy it on the mobile health side, where we've merely begun to scratch the surface. So I believe the transport business will keep expanding. I'm quite enthusiastic about the chance to leverage the tech platform to oversee the ambulances in the field, but now to leverage the fly cars, as we refer to them in the field within the mobile health space, which once more we're only scratching the surface of, and I believe the market will greatly value the tech platform now within the mobile healthcare space as we've expanded into that opportunity.
Richard Close
analystIf you're looking for 15% growth, Norm, what should the quarterly cadence look like across 2025? Because Q3 came in around 1.7%, if I'm reading that correctly, and something like 1% to 2% in Q2 or Q4?
Norman Rosenberg
executiveRight. At the risk of sounding extremely linear, my view is it will be fairly linear, and here's why: there are a few hospitals — in New York State, let's say — that we now serve. We haven't issued the press release yet since we're awaiting sign off, but work is already underway. So we've started working with certain hospital systems, and those will ramp over time. A few others, we believe, are at the one yard line or two yard line heading in, and those likely won't be a Q1 event — they'll probably land at some point in Q2, then ramp through Q3 and Q4. So purely from how the pipeline looks, you'll capture the full benefit once you reach Q3 and Q4, particularly Q4. My expectation, then, is that it works its way up sequentially over the course of the year. I'd anticipate transport revenues in Q1 exceeding Q4, and higher in Q2, Q3, Q4 and so forth as we close out 2025.
Matt Shea
analystHi, this is Matt Jay, filling in for Ryan. Regarding the migrant revenues for 2025, is there any chance the remaining portion gets accelerated even more, or do you have pretty solid visibility from this point? And I understand that if it winds down more quickly, you'll be able to substitute core revenues for it; but since there's a cost impact during the transition, I'm trying to assess the risk that the wind down gets accelerated further and ends up weighing on the EBITDA outlook.
Lee Bienstock
executiveYeah. Hey, Matt, this is Lee. Glad to address that, since I've been deeply involved in this entire process. I'd say yes, it's entirely possible it could come in below the $50 million given the current administration and what's happening in the political landscape. So it's definitely possible it could be under $50 million. I'd say we would move that personnel especially toward the opportunities I laid out in the prepared remarks. That's why we're essentially taking that EBITDA guidance we provided at the end of last year and lowering it, correct; so it will require investment and it will cost us some margin to shift, as you said, from that staff to new opportunities, and that's why we're factoring it in with the lower — in part with the lower EBITDA margin guide we just adjusted on this call.
Matt Shea
analystIt sounds like that's already baked into the guidance. Given how much faster you're moving into payers, I'd appreciate any update on what you're targeting for the payer business. You said before that you'd reach a 1,000 care gap run rate by the end of 2024, and I believe that would position you for 65,000 care gap closures in 2025, with hopes of getting 10,000 primary care patients and 70,000 patients onto virtual care management. Are those numbers still your targets, or are you rethinking how far the business could go now that the payer rollout is speeding up?
Lee Bienstock
executiveYes. I'd say those targets remain in place. As we move through the year, we'll provide updates on them. There are a few ways we think about this. Yes, at the close of last year we got very near that 1,000 visits a week. Right now, as we begin the year, we're running at roughly 400 to 500 visits each week. For health plans, the start of the year is seasonally something of an introductory period, so we're keeping pace with their cadence. To give you a sense of the scale, we believe our exit rate at the end of this year will exceed 2,000 visits per week, as we assist health plans in closing out the year and reaching patients who do indeed still have open gaps; so we expect to keep stepping up the care gap visits, and 65,000 care gap visits is definitely the objective. I'd add that we've brought on PTI Health, which handles mobile phlebotomy in the home, and now that they've joined the Daco family, we're exploring ways to broaden their scope of services too. So we'll keep updating those metrics. Our contracting with the health plans is advancing, moving toward becoming the PCP provider as well as closing care gaps. So our goal there is unchanged too — to enroll 10,000 PCP patients and, as we said, around 70,000 patients monitored as well. So as we sign contracts, we'll keep updating. As I noted, a great deal of this pipeline was factored in when we provided our targets and guidance for this year. But as we keep ramping and scaling, we'll keep updating those.
Analyst
analystThanks for that, Lee. Perhaps just a final one regarding the municipal segment. There are, I believe, two components to what I'm asking. To start, during the previous quarter, you brought up what I think was termed the Project Prime initiative, aimed at pinpointing sizable contractors who could gain from subcontracting population health work to DocGo. Is there anything you can share about that? I recall early 2025 was possibly when we'd begin seeing some movement, so I'd appreciate any news on that front. Then secondly, more generally, since municipal programs' funding can be shaped by federal policy, I'd like to hear what you think about how shifts in Washington might affect your muni operations, or government work more broadly? Thanks everyone.
Lee Bienstock
executiveCertainly. So our Project Prime, as you brought up, involves us teaming up and executing agreements with service providers already serving municipal bodies like the VA, and it's moving along nicely. Like I said, we executed 2 subcontractor agreements to deliver services for existing contractors already serving the VA. That's essentially our approach to growing into that area; and as I noted, we executed 2 agreements and our team, once more, has a pipeline of additional prospects we're actively pursuing. So it's making headway. As I stated, we already executed 2 agreements as part of this effort and we'll keep putting resources there too. And that's the aim. Regarding what's being communicated from Washington, I believe at present our aim has truly been to pursue evergreen prospects that represent necessities for municipal government across decades and we expect will remain so. For instance, delivering care to our veterans is a strong illustration. We'll discuss others once we begin advancing the pipeline further, but those serve as excellent instances of areas that are fairly apolitical and bipartisan—giving medical care to our veterans—which has existed for decades and we expect those are precisely the kinds of prospects that will exist going forward and the evergreen style municipal programs we're chasing. I think that's basically our stance at the moment concerning how things are developing on the municipal front. We're centered on delivering enormous ROI, extending care to populations lacking solid access to it. We accomplish this in a more cost efficient manner, which once more also matches certain messaging emerging from Washington presently, where we actually do it with greater cost efficiency and better ROI by delivering dynamic care to underserved populations, consequently enhancing health outcomes, which reduces the overall cost of care. So we sense we're genuinely aligned with the correct side of this trend.
David Larsen
analystI believe you mentioned migrant revenue came to 55 million for the quarter, which suggests your base was roughly 66 million during that period. Annualizing that gives you 260 million in base revenue, and adding 50 million for migrant revenue brings you to about 313 million for the year. The guide appears to be around 430 million, so that leaves a gap of roughly $120 million. Assuming 1,000 care gap visits weekly at $300 each, that comes to somewhere near $15 million or $20 million, meaning another $100 million in revenue remains to be captured. So how much of that must you go win versus what's already under contract? Thanks — any confidence you can offer on what's identified. It's in the CRM, we're in late-stage talks for about $50 million of that $100 million, or half of it is already signed. More detail would be really useful.
Norman Rosenberg
executiveHey, David, this is Norm Rose. I'll begin and perhaps, Lee, you can fill in some gaps. The first place I'd start is our transport business, where we did roughly $194 million. We're projecting about $225 million for next year, so that's roughly a $30 million increase; we feel quite good about that figure, going through them line by line. If we look at everything currently contracted, I think we should be able to reach that number. Of course, that will depend on how fast we can ramp up or boost some volumes in certain locations, correct? Everything is subject to that sort of thing, but that's contracted, that's committed. In fact, if anything, some items in the pipeline that Lee mentioned weren't included in that 2.25% and would be additive to it; so there might be some potential upside there. Otherwise, regarding our various businesses, obviously, we have the PTI company that came in, which combined with HPP is somewhat higher than perhaps your $20 million the payer program, somewhat higher than your $20 million figure. And then broadly around some other areas, I'd say most of it is already accounted for or closed. I'd say there's probably still around the $25 million range or so mostly on the municipal mobile health side where those things aren't contracted yet. They're covered by our fees, meaning I can point to certain contracts where if those came through, we would get there. So we're aware that we're already two months into the year, so we'd need to be in that sort of situation. But I'd say the go get is probably maybe that $25 million within the municipal mobile health space specifically.
Analyst
analystHello, my name is Aditya, and I'm calling in for Mike Latimore. Could you provide some insight regarding cash flow from operations — for instance, what figure do you anticipate for cash flow from operations when expressed as a percentage of EBITDA?
Norman Rosenberg
executiveCertainly. Let me take you back to examine the current year; during this year, our cash flow from operations — you'll find it in the release, and it also appears in the 10-K we filed — came to roughly $70 million, and that is compared with approximately $60 million of EBITDA. That just provides a sense that during this year our cash flow from operations exceeded the EBITDA figure, even though EBITDA clearly serves as a proxy, or adjusted EBITDA serves as a proxy, for cash flow — but this happened because we enjoyed favorable working capital movements, including collections of receivables, with receivables declining by roughly $50 million year-over-year. Consequently, we managed to surpass that figure through operating cash flow. In our script, within our prepared comments, we discussed how we anticipate that no matter where EBITDA margins land, we completely expect to produce meaningful — and I believe the earnings release noted this too — we expect to produce meaningful cash flow from operations, exceeding what we achieved in 2024; that is purely because we have a great deal of this migrant revenue outstanding — specifically the migrant AR outstanding that has begun to come in. One point worth noting is that at year-end, we held approximately $150 million in accounts receivable tied to those migrant programs, spanning New York City Housing Preservation Development, known as HPD, which accounts for a bit over $70 million, and H&H, which accounts for roughly $79 million. Combined, those two come to approximately $150 million, and offsetting that we carry about $30 million in accounts payable. So a substantial amount remains outstanding that we are currently working to collect, which ought to assist us in pushing that operating cash flow upward.
Analyst
analystAnd how much of the total was spent on subcontracted labor?
Norman Rosenberg
executiveWell, it has decreased fairly substantially. I'd say our highest point was likely Q4 of the prior year. It exceeded 40% back then. That happened during the peak of the migrant projects, when we were still working to ramp up our own W2 labor. Looking company-wide, I'd put the figure at roughly 24%. So there's been a pretty meaningful drop; as I noted, we do carry subcontracted labor costs in both mobile health and transport; on the transport side, in one of our markets, that figure ran somewhat above where it ought to have been. As a result, margins on the transport side were held down — rather than 30.1% for the quarter, it likely would have come in nearer 32%. Apart from that, it's all resolved at this point. Those subcontractors are no longer involved. So my expectation is that subcontractor spend as a share of revenue will keep falling as we head into Q1. It should land below 20% of revenue.
Aidan Conniff
analystAidan Conniff here, filling in for David. Could you give us a bit more color on what's behind your total OpEx assumptions for the year?
Norman Rosenberg
executiveAbsolutely. Once more, the best lens here is OpEx as a share of revenue — that's the approach we're using to work backwards and solve for it; and it also helps to view it alongside our Q4 results and the quarters before that. What we're assuming, then, is that gross margins land quite close to the full year 2024 figure. That full year 2024 number came in at 34.6%. We expect to be around 35%, possibly slightly above, since a handful of factors were holding that figure down and brought us to 34.6%. The underlying level, we believe, ought to be 35%. Worth keeping in mind, as Lee mentioned during his remarks, that gross margin has not weakened even while revenue figures have been falling; so on a marginal or variable cost footing, we're definitely holding our own and performing well. Assuming that holds, and assuming we're discussing a mid single digit figure — let's say a 5% EBITDA margin — that implies roughly 30%; meaning SG&A would average about 30% of revenue across the year; for some perspective, as we noted for this quarter, in this fourth quarter, with everything that gets layered in, we landed at roughly 39.7%. During the third quarter we came in below 30%. So my sense is that our final figure will run somewhat above the trend we'd seen, say, in Q2 and Q3 of this year, reflecting certain investments we've discussed, yet clearly far under the Q4 level as a percentage, even with revenue declining as more of the migrant-related activity begins to fall away. And once we reach the back half of the year, when growth in some of this core business truly takes hold and the revenue figure climbs sequentially, that percentage likely comes down. Looking at the whole year from the top down, though, I believe that figure ought to sit at roughly 30% of revenue.
Aidan Conniff
analystThanks for the pipeline details — that helped. How are you all viewing the conversion of that pipeline across the year, and how deals land over time?
Lee Bienstock
executiveYeah, for sure. What we see is that it truly hinges on the vertical — which customer vertical it is. At the close of last year, I think we witnessed a burst of deal activity on the payer side. We expect that same pattern again in this year. There are certain deals we're currently putting into operation. And I also believe that as the year wraps up, plans genuinely begin concentrating on their unattributed members, their unengaged members, and truly on shutting care gaps to finish the year strong. That's the basis on which they're measured. So at the close of last year we made a major push; we succeeded at that, and certain deals have kept arriving as this year began; and then I think around Q3, Q4 too, we'll begin seeing once more a rise in filling the top of the funnel for that pipeline. When it comes to medical transportation and hospital systems, it stays fairly steady all year long. As Norm said, we have several opportunities sitting at the one yard line right now. We're extremely, extremely confident about four deals we've already signed that are in a sort of ramp and expansion mode. And on that specific medical transportation and hospital system side, it's fairly even as we move through the year. And regarding the municipal side, one aim of Project Prime is to smooth out, so to speak, the pipeline, since municipal work tends to be heavily RFP driven and binary and perhaps more lumpy. Our efforts with the prime vendors will help us smooth that out as we begin helping them expand contracts or services they already deliver in the field. So that's a piece of that initiative; so I think we'll begin seeing some smoothing of the pipeline; we keep adding opportunities near the top of the funnel, and we signed a burst of activity toward the end of the year and the start of this year, and we're going to keep working that pipeline as aggressively as we possibly can.
Lee Bienstock
executiveThank you so much. Thank you to everyone for joining us and be well.
Operator
operatorEveryone, that brings us to the end of today's conference call. We appreciate you joining us. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.